Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Klarman’s Top Small-Cap Picks: ViaSat Inc., Theravance Inc., PBF Energy

Page 1 of 2

The Baupost Group is a Boston-based hedge fund founded and operated by billionaire Seth Klarman. Klarman’s fund is one of the biggest and most successful hedge fund firms in the world, ranking fourth in net gains since its founding, according to Bloomberg. His main fund has generated an annualized return of as much as 17% after fees since its inception. By the same token, Seth Klarman has acquired a reputation as one of the best-performing hedge fund managers in the history of finance by generating more than $21 billion in returns throughout his career. Klarman is mostly-known as a value investor, who uses little or no leverage in his investments except for the real estate sector. The most recent 13F filing shows that Klarman’s ample equity portfolio consists of 28 active positions and is valued at $5.95 billion. In this article we’ll analyze Klarman’s top small-cap holdings in the following companies: ViaSat Inc. (NASDAQ:VSAT), Theravance Inc. (NASDAQ:THRX), PBF Energy Inc. (NYSE:PBF) and Keryx Biopharmaceuticals Inc. (NASDAQ:KERX).


While we track the latest moves of funds, we are in fact more interested in their 13F filings, which we use to determine the top 15 small-cap stocks held by the funds in our database. We gather and share this information based on 16 years of research, with backtests for the period between 1999 and 2012 and forward testing for the last 32 months. The results of our analysis show that these 15 most popular small-cap picks have great potential to outperform the market, beating the S&P 500 Total Return Index by nearly one percentage point per month on average in backtests. Moreover, since the beginning of forward testing in August 2012, the strategy worked splendidly, outperforming the market every year and returning 139% through the end of April, which is more than 80 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).

The Baupost Group did not change its stake in ViaSat Inc. (NASDAQ:VSAT), its top small-cap pick, during the first quarter. The hedge fund still owns slightly more than 11.53 million shares valued at $687.49 million as of March 31. ViaSat shares are mostly flat in 2015, having increased by 1% since the beginning of the current year. The innovator in broadband and communication technologies and services delivered a strong financial performance in the latest quarter, beating the expectations of Wall Street analysts. ViaSat generated revenues of $364.8 million during its fiscal fourth quarter of 2015, which ended on April 3, hitting a new record high. Additionally, the fiscal fourth quarter net income delivered by ViaSat amounted to $7.5 million, which is indisputably higher than the loss reported during the same period one year prior. To sum up, it seems that ViaSat’s stock might get right back on its desired path as funds like Jeffrey Bronchick‘s Cove Street Capital and FPR Partners keep increasing their holdings in ViaSat Inc. (NASDAQ:VSAT).

The Baupost Group also did not make changes to its equity stake in Theravance Inc. (NASDAQ:THRX) maintaining its 19.82 million share position, valued at $311.51 million. Despite the fact that shares of Theravance have achieved a rise of more than 15% since the beginning of the year, it is expected that the stock price could go even higher, as the U.S. Food and Drug Administration approved BREO® ELLIPTA® for the treatment of asthma on April 30. Additionally, the company has recently announced a $0.25 cash dividend that will be paid at the end of June and amounts to a solid 6.01% yield, which undoubtedly signals that the company is currently in good financial health. Some other funds bullish on Theravance Inc. (NASDAQ:THRX) include Youlia Miteva’s Proxima Capital Management and Richard Perry’s hedge fund Perry Capital.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!